Cancer testis antigen and immunotherapy

The identification of cancer testis (CT) antigens has been an important advance in determining potential targets for cancer immunotherapy. Multiple previous studies have shown that CT antigen vaccines, using both peptides and dendritic cell vaccines, can elicit clinical and immunologic responses in...

Descripción completa

Detalles Bibliográficos
Autores principales: Krishnadas, Deepa Kolaseri, Bai, Fanqi, Lucas, Kenneth G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928360/
https://www.ncbi.nlm.nih.gov/pubmed/27471684
http://dx.doi.org/10.2147/ITT.S35570
_version_ 1782440426513367040
author Krishnadas, Deepa Kolaseri
Bai, Fanqi
Lucas, Kenneth G
author_facet Krishnadas, Deepa Kolaseri
Bai, Fanqi
Lucas, Kenneth G
author_sort Krishnadas, Deepa Kolaseri
collection PubMed
description The identification of cancer testis (CT) antigens has been an important advance in determining potential targets for cancer immunotherapy. Multiple previous studies have shown that CT antigen vaccines, using both peptides and dendritic cell vaccines, can elicit clinical and immunologic responses in several different tumors. This review details the expression of melanoma antigen family A, 1 (MAGE-A1), melanoma antigen family A, 3 (MAGE-A3), and New York esophageal squamous cell carcinoma-1 (NY-ESO-1) in various malignancies, and presents our current understanding of CT antigen based immunotherapy.
format Online
Article
Text
id pubmed-4928360
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49283602016-07-28 Cancer testis antigen and immunotherapy Krishnadas, Deepa Kolaseri Bai, Fanqi Lucas, Kenneth G Immunotargets Ther Review The identification of cancer testis (CT) antigens has been an important advance in determining potential targets for cancer immunotherapy. Multiple previous studies have shown that CT antigen vaccines, using both peptides and dendritic cell vaccines, can elicit clinical and immunologic responses in several different tumors. This review details the expression of melanoma antigen family A, 1 (MAGE-A1), melanoma antigen family A, 3 (MAGE-A3), and New York esophageal squamous cell carcinoma-1 (NY-ESO-1) in various malignancies, and presents our current understanding of CT antigen based immunotherapy. Dove Medical Press 2013-04-17 /pmc/articles/PMC4928360/ /pubmed/27471684 http://dx.doi.org/10.2147/ITT.S35570 Text en © 2013 Krishnadas et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Krishnadas, Deepa Kolaseri
Bai, Fanqi
Lucas, Kenneth G
Cancer testis antigen and immunotherapy
title Cancer testis antigen and immunotherapy
title_full Cancer testis antigen and immunotherapy
title_fullStr Cancer testis antigen and immunotherapy
title_full_unstemmed Cancer testis antigen and immunotherapy
title_short Cancer testis antigen and immunotherapy
title_sort cancer testis antigen and immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928360/
https://www.ncbi.nlm.nih.gov/pubmed/27471684
http://dx.doi.org/10.2147/ITT.S35570
work_keys_str_mv AT krishnadasdeepakolaseri cancertestisantigenandimmunotherapy
AT baifanqi cancertestisantigenandimmunotherapy
AT lucaskennethg cancertestisantigenandimmunotherapy

Ejemplares similares